Dr. Perales on the Future of CAR T-Cell Therapy in DLBCL and Follicular Lymphoma

Video

Miguel-Angel Perales, MD, discusses the future of CAR T-cell therapy in diffuse large B-cell lymphoma and follicular lymphoma.

Miguel-Angel Perales, MD, deputy chief, Adult Bone Marrow Transplant Service, director, Adult Bone Marrow Transplantation Fellowship Program, Memorial Sloan Kettering Cancer Center, discusses the future of CAR T-cell therapy in diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma.

There is potential to move CAR T cells earlier in treatment of patients with DLBCL and follicular lymphoma, says Perales. Studies have examined earlier CAR T-cell therapy in mantle cell lymphoma, while other studies looked at combining CAR T cells with checkpoint inhibitors. The results of those studies still need to be released, says Perales.

The results of CAR T-cell therapy in follicular lymphoma are promising, he adds. A study from the University of Pennsylvania looked at a small group of 14 patients and showed positive survival curves with this approach. Another study examined a different small group of patients with follicular lymphoma versus patients with transformed follicular lymphoma. Results from the study showed that patients with follicular lymphoma responded better to CAR T-cell therapy than those with transformed follicular lymphoma. These results were similar to that of the study conducted at the University of Pennsylvania, concludes Perales.

Recent Videos
Jeffrey Chamberlain, PhD
Tami John, MD
Tami John, MD
Tami John, MD
Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, an associate professor and the lymphoma stream lead at St Vincent’s Hospital
Saurabh Dahiya, MD, FACP, an associate professor of medicine at Stanford University School of Medicine; as well as clinical director of Cancer Cell Therapy in the Division of Blood and Marrow Transplantation and Cell Therapy at Stanford Medicine
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Laura Aguilar MD, PhD, the chief medical officer of Diakonos Oncology
Related Content
© 2025 MJH Life Sciences

All rights reserved.